What is Fara?
Fara operates as a specialized nonprofit entity dedicated to the eradication of Friedreich's ataxia, a debilitating neurodegenerative condition. The organization functions as a central hub for the FA research community, orchestrating a complex ecosystem of grant-making, clinical trial support, and global advocacy. By maintaining a rigorous focus on scientific excellence and patient-centric outcomes, Fara has established itself as a primary catalyst for innovation in the rare disease sector. Its operational model integrates direct research investment with the cultivation of a global network of scientists, clinicians, and affected families, thereby accelerating the development of potential treatments and improving the quality of life for those impacted by the disease.
How much funding has Fara raised?
Fara has raised a total of $227K across 2 funding rounds:
Debt
$150K
Debt
$77K
Debt (2020): $150K with participation from PPP
Debt (2021): $77K led by PPP
Key Investors in Fara
PPP
Public-Private Partnership
What's next for Fara?
With the recent influx of capital, Fara is positioned to scale its strategic initiatives, particularly in the realm of late-stage clinical trials and translational medicine. The organization's roadmap involves deepening its investment in high-potential research projects that demonstrate the greatest promise for disease modification. Furthermore, Fara intends to expand its advocacy programs, ensuring that the patient voice remains at the forefront of regulatory and scientific discourse. As the organization moves into this next phase of growth, the focus will remain on optimizing the research pipeline and fostering collaborative partnerships that can translate scientific progress into tangible clinical results for the global FA community.
See full Fara company page
